Perjeta Market: Access, Delivery, and Competition in HER2 Treatment

Introduction to the Perjeta Market Landscape

Beyond clinical performance, the Perjeta market is shaped by how treatment is delivered, how competitors are positioning themselves, and how patients obtain specialty medicines. The global Perjeta market was valued at USD 4.24 billion in 2024 and is projected to reach USD 7.13 billion by 2034, according to Polaris Market Research.

Advancements in Treatment Delivery

Innovations such as fixed-dose combinations and subcutaneous formulations have streamlined administration, reducing the need for prolonged infusion times and hospital visits. In April 2025, Roche received a positive CHMP opinion for EU label updates to Phesgo (pertuzumab/trastuzumab). The update allows subcutaneous administration by healthcare professionals in nonclinical settings, such as homes, after clinical establishment for HER2+ breast cancer treatment.

These enhancements improve patient compliance and satisfaction while optimizing healthcare resource utilization.

Expanding Approvals and Evolving Guidelines

Regulatory endorsements for early-stage, neoadjuvant, and metastatic settings have solidified Perjeta's role across multiple stages of disease progression. In March 2022, Chugai Pharmaceutical received MHLW approval for Perjeta and Herceptin biosimilars to treat unresectable, advanced or recurrent HER2-positive colorectal cancer progressing after chemotherapy. Updates from global oncology bodies often incorporate Perjeta-based regimens as preferred options, which improves prescriber confidence and opens new patient pools.

Research activity continues across HER2-targeted therapies. In April 2025, AstraZeneca and Daiichi Sankyo's DESTINY-Breast09 Phase III trial showed that Enhertu plus pertuzumab improved progression-free survival versus standard THP therapy in HER2+ metastatic breast cancer. Results like these keep HER2-targeted therapies at the center of oncology planning.

Biosimilar Competition and Competitive Positioning

While biosimilar versions of HER2 drugs may provide cost advantages, the originator biologics maintain their unique therapeutic value and clinical distinction. Competitive analysis in the report indicates that biosimilar developers such as Biocon, Amgen, and Celltrion are accelerating trials to capitalize on latent demand in cost-sensitive regions.

Recent activity illustrates this shift. In June 2024, Zydus and Dr. Reddy's entered a licensing agreement to co-market a pertuzumab biosimilar for HER2+ breast cancer in India. Samsung Bioepis, established in 2012 and now a wholly owned subsidiary of Samsung Biologics, is recognized for its oncology biosimilars, including trastuzumab, a biosimilar to Herceptin. Its expertise in monoclonal antibody biosimilars positions it as a potential future player in the pertuzumab biosimilar space as patents expire. FDA and EMA regulatory pathways for biosimilars are also reshaping competitive dynamics, and biosimilar manufacturers use formats such as pre-filled syringes to strengthen positioning.

Distribution Channels and Digital Access

The Perjeta market is segmented by distribution channel into hospital pharmacies, specialty pharmacies, and online pharmacies. The online pharmacies segment is expected to witness the fastest growth during the forecast period. This reflects a shift in consumer behavior toward digital healthcare navigation platforms and rising demand for convenient access to specialty medications. Online channels offer improved accessibility, privacy, and ease of procurement for patients on long-term cancer therapies. Advances in e-commerce infrastructure and telemedicine integration also support patients in remote or underserved regions.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/perjeta-market 

Regional and Competitive Context

North America was the largest market in 2024, while Asia Pacific is projected to witness the fastest growth. In Asia Pacific, healthcare access initiatives, the gradual adoption of western treatment protocols, and the availability of biosimilars are supporting expansion opportunities. In Germany, a January 2025 study in Nature Medicine found that AI improved breast cancer detection by 18% in the national screening program, identifying 6.7 versus 5.7 cancers per 1,000 women without increasing false positives, which supports identification of patients eligible for targeted therapy.

The key players named in the report are F. Hoffmann-La Roche Ltd; Biocon; Samsung Bioepis; Pfizer Inc.; Genentech, Inc.; Dr. Reddy's Laboratories Ltd.; and CELLTRION INC.

Conclusion

The Perjeta market is supported by the continued clinical importance of HER2-targeted therapies in treating eligible patients with HER2-positive breast cancer. Growing emphasis on biomarker-based treatment selection and personalized oncology care is supporting the utilization of targeted therapeutic approaches. Advances in cancer diagnostics, treatment protocols, and combination therapy strategies are contributing to developments in the broader HER2-directed treatment landscape. Additionally, improving access to specialized oncology services in developing healthcare markets may create opportunities for treatment adoption. However, high treatment costs, reimbursement limitations, potential adverse effects, and competition from alternative HER2-targeted therapies remain important market considerations. Overall, the market outlook will depend on clinical treatment preferences, patient access, competitive developments, and the evolving oncology therapeutic landscape.

More Trending Latest Reports By Polaris Market Research:

Riflescope & Red Dot Sight Market

Singapore, Malaysia, and China Corporate Secretarial Services Market

Asset Management System Market

T4 DNA Ligase Market

Singapore, Malaysia, and China Corporate Secretarial Services Market

Substation Automation Market

Custom Printing Market

Autonomous Tractors Market: The New Era of Farming

U.S. Sterilization Monitoring Market